Press Release

United States Clinical Oncology Next Generation Sequencing Market to Grow with a CAGR of 9.12% through 2028

Growth in genomic medicine is expected to drive the United States Clinical Oncology Next Generation Sequencing Market growth in the forecast period, 2024-2028.


According to TechSci Research report, “Clinical Oncology Next Generation Sequencing Market – United States Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the United States Clinical Oncology Next Generation Sequencing Market stood at USD 159.21 million in 2022 and is anticipated to grow with a CAGR of 9.12% in the forecast period, 2024-2028. The field of clinical oncology has witnessed a significant transformation over the years, with advances in genomics and molecular biology leading to more precise and personalized cancer care. One of the driving forces behind this transformation is Next Generation Sequencing (NGS), a high-throughput DNA sequencing technology that has enabled researchers and clinicians to decode the genetic intricacies of cancer cells. The prevalence of cancer in the United States continues to climb, making it a significant public health concern. According to the American Cancer Society, approximately 1.8 million new cancer cases are expected in 2023. This growing cancer burden necessitates more advanced and precise diagnostic and treatment methods, making NGS a valuable tool in the oncologist's arsenal. NGS allows for a comprehensive analysis of the genetic mutations that drive cancer, aiding in the development of targeted therapies and personalized treatment plans.

The concept of personalized medicine, also known as precision medicine, is gaining momentum in oncology. Each patient's cancer is unique, and tailoring treatment to the individual's genetic profile is a game-changer. NGS enables oncologists to identify specific genetic alterations in a patient's tumor, allowing for the selection of therapies that are most likely to be effective. As a result, patients may experience better outcomes with fewer adverse effects.

NGS technologies have evolved rapidly, becoming more accessible and cost-effective. The United States is at the forefront of NGS development, with companies and research institutions continuously pushing the boundaries of technology. Improved sequencing accuracy, faster turnaround times, and reduced costs have made NGS a practical choice for clinical applications. These advancements in technology have opened the door to wider adoption in clinical oncology.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "United States Clinical Oncology Next Generation Sequencing Market.”


NGS is not only valuable for diagnosing cancer and guiding treatment decisions but also plays a crucial role in drug development and clinical trials. Pharmaceutical companies use NGS to identify potential therapeutic targets and assess the efficacy of new drugs. Additionally, NGS is integral in patient stratification for clinical trials, helping to identify the most suitable candidates for experimental therapies.

The United States Clinical Oncology Next Generation Sequencing Market is segmented into Ingredient type, form, livestock, Regional Distribution, And Company.

Based on the Application, the Companion Diagnostics segment emerged as the dominant player in the United States market for United States Clinical Oncology Next Generation Sequencing Market in 2022. Companion diagnostics are at the forefront of precision medicine in oncology. By identifying specific genetic or molecular alterations in a patient's tumor, these tests enable oncologists to select therapies that are more likely to be effective for that individual. This approach optimizes treatment outcomes and minimizes unnecessary exposure to treatments with potential side effects. Companion diagnostics are instrumental in tailoring cancer treatments to the unique genetic profile of each patient. The ability to match patients with the most appropriate therapies, such as targeted agents or immunotherapies, is transforming the oncology field by increasing the likelihood of therapeutic success. Regulatory agencies, including the U.S. Food and Drug Administration (FDA), have been actively supporting the development and approval of companion diagnostics. This regulatory backing enhances the confidence of healthcare providers and patients in the clinical utility of CDx, driving their widespread adoption. Companion diagnostics assist healthcare providers in making informed clinical decisions. They provide critical insights into which treatments are likely to be effective for a particular patient and can also help identify individuals who may not respond well to certain therapies, preventing unnecessary exposure to potentially ineffective treatments.

Based on the End Use, the Hospitals segment emerged as the dominant player in the United States market for United States Clinical Oncology Next Generation Sequencing Market in 2022. Comprehensive Patient Care: Hospitals are often the primary providers of comprehensive cancer care, offering services that span from diagnosis to treatment and follow-up care. NGS technology is integral to this continuum, as it allows for precise cancer diagnosis and personalized treatment planning. Hospitals utilize NGS to offer patients a one-stop solution for their oncological needs. Hospitals typically have more extensive clinical capabilities compared to clinics and laboratories. This includes access to a wide range of medical specialists, advanced imaging, radiation therapy, and surgical services. NGS serves as an essential tool within this comprehensive framework, aiding in the diagnosis of complex or advanced cancer cases. Hospitals provide inpatient care, making them well-suited for patients with severe or advanced cancer who may require hospitalization. NGS is used in these settings to guide treatment decisions, monitor disease progression, and assess treatment responses for patients admitted to the hospital.

Mid-West emerged as the dominant player in the United States Clinical Oncology Next Generation Sequencing Market in 2022, holding the largest market share. The East region, particularly in areas such as Boston, New York, and the Greater Washington, D.C. area, is home to a high concentration of prestigious healthcare institutions, academic medical centers, and research universities. These institutions are at the forefront of cancer research, clinical trials, and the adoption of cutting-edge medical technologies like NGS. The East region fosters collaborations between academic institutions, healthcare providers, and biotechnology companies, driving research and innovation. These collaborations often lead to the development and implementation of NGS technologies in clinical oncology. The proximity to the U.S. FDA and other regulatory agencies in the Greater Washington, D.C. area means that the East region is often at the forefront of regulatory approvals and guidelines related to NGS technologies in clinical applications. This close relationship with regulatory bodies ensures a clear regulatory pathway for the adoption of NGS in clinical oncology.


Major companies operating in United States Clinical Oncology Next Generation Sequencing Market are:

  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd.
  • Agilent Technologies
  • Myriad Genetics
  • Beijing Genomics Institute (BGI)
  • Perkin Elmer
  • Foundation Medicine
  • Pacific Bioscience
  • Oxford Nanopore Technologies Ltd.
  • Macrogen, Inc.
  • Qiagen NV


Download Free Sample Report

Customers can also request for 10% free customization on this report.


 “The United States Clinical Oncology Next Generation Sequencing (NGS) market is poised for significant growth in the coming years. Anticipated advancements in NGS technology, coupled with increased recognition of its role in precision medicine, are driving demand. The market is set to benefit from expanded applications of NGS in cancer diagnosis, treatment, and research, with a focus on comprehensive tumor profiling and personalized therapeutic approaches. Regulatory support and the development of clear guidelines for NGS-based diagnostics will further bolster confidence in this technology, making it an integral part of clinical oncology practice. Additionally, the rising awareness of the potential benefits of NGS among healthcare professionals and patients is expected to contribute to market expansion.” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

United States Clinical Oncology Next Generation Sequencing Market Segmented By Technology (Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing & Resequencing Centrifuges), By Workflow (NGS Pre-Sequencing, NGS Sequencing, NGS Data Analysis), By Application (Screening, Companion Diagnostics, Other Diagnostics), By End Use (Hospitals, Clinics, Laboratories) Region and Competition, Opportunity, and Forecast, 2018-2028”, has evaluated the future growth potential of United States Clinical Oncology Next Generation Sequencing Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United States Clinical Oncology Next Generation Sequencing Market.



Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]


Relevant News